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Glycoprotein incorporationOrthopoxviruses produce two, antigenically distinct, infectious virions, intracellular mature virions and
extracellular virions (EV). A33 and B5 are found on EV but not on intracellular mature virions. To investigate
the function of A33, a recombinant virus that has A33R deleted and expresses B5R-GFP (vB5R-GFP/ΔA33R)
was generated. A comparison of vB5R-GFP/ΔA33R to an analogous virus (vΔA33R) revealed an additional
defect in infectious EV production that was not apparent when A33R was present. Characterization of these
recombinants revealed that EV produced in the absence of A33 had undetectable levels of B5-GFP. Both
recombinants released similar amounts of EV but there were differences in their infectivity. Approximately
equal numbers of virions produced by these recombinants were able to bind cells even though EV produced
by vB5R-GFP/ΔA33R do not contain B5. These results suggest that in the absence of A33, the cytoplasmic tail
of B5 contributes to its incorporation into the envelope of progeny virions.and Immunology, University of
14642, USA. Fax: +1 585 473
.M. Ward).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Vaccinia virus is the best-studied member of the Orthopoxvirus
genus. It has a double-stranded DNA genome of about 200 kb that is
predicted to encode for approximately 200 functional open reading
frames (Moss, 2001). Viral replication occurs entirely in the cytoplasm
of infected cells in a specialized area known as the viral factory and
results in three commonly recognized, morphologically distinct,
forms: intracellular mature virions (IMV), intracellular enveloped
virions (IEV), and extracellular virions (EV) (Moss, 2006; Smith et al.,
2002). IMV is the ﬁrst infectious progeny virions formed and
represents the majority of virions produced by infected cells. IEV are
formed by intracellular envelopment of a subset of IMV with an
additional double membrane derived from the trans-Golgi network
(TGN) or early endosomes (Hiller and Weber, 1985; Schmelz et al.,
1994; Tooze et al., 1993). IEV are transported to the cell periphery via
microtubules and released from the cytoplasm by fusion of their
outermost envelope membrane with the plasma membrane (Geada
et al., 2001; Hollinshead et al., 2001; Rietdorf et al., 2001; Ward and
Moss, 2001a). These released virions have lost one of their IEVmembranes but possess onemoremembrane than IMV and have been
called EV. EV can be further classiﬁed as being either cell-associated
enveloped virions (CEV) or extracellular enveloped virions (EEV) for
those virions that have detached from the cell they were produced in.
CEV are believed to be important for efﬁcient cell-to-cell spread via
actin tails (Reeves et al., 2005; Ward and Moss, 2001a) while EEV
mediate greater dissemination of virus (Appleyard et al., 1971; Payne,
1980).
Presently, six proteins encoded by the virus, A33, A34, A36, B5, F12,
and F13, have been found to be both exclusive to either IEV or EV and
involved in infectious EV production (Duncan and Smith, 1992;
Engelstad et al., 1992; Hirt et al., 1986; Isaacs et al., 1992; Roper et al.,
1996; van Eijl et al., 2002, 2000). A33 is predicted to play a role in both
IEV/EV morphogenesis/egress and subsequent infection. A33R is
highly conserved among orthopoxviruses and encodes a 23 kDa type
II glycoprotein (Roper et al., 1996). Deletion of A33R results in a
reduction in IEV production and an increase in infectious EEV
production (Roper et al., 1998). The cytoplasmic tails of A33 and
A36 interact and the interaction is required for the incorporation of
A36 into IEV and subsequently, actin tail formation (Ward et al., 2003;
Wolffe et al., 2001). It has also been reported that A33 interacts with
B5 (Perdiguero and Blasco, 2006). The crystal structure of the
ectodomain of A33 suggests that it contains an unusual C-type
lectin-like domain that may interact with host cells (Su et al., 2010).
Here, we have created a recombinant vaccinia virus that has A33R
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virus was more defective than the parental virus vΔA33R. Character-
ization of these viruses revealed that in the absence of A33, B5-GFP
was not found on EV. Quantiﬁcation of progeny EV produced by these
recombinants shows that the absence of A33 only slightly reduces the
amount of EV produced in addition to making them less infectious.
The removal of B5, in addition to A33, from EV further reduces the
infectivity of EV but this reduction is not due to a reduction in the
ability to bind cells.Results
Construction and characterization of a recombinant virus that expresses
B5R-GFP and has A33R deleted
A recombinant virus expressing B5R fused to the coding sequence
of enhanced GFP in place of normal B5R (vB5R-GFP) has been useful
for studying virion egress in living cells (Ward, 2009; Ward and Moss,
2001b). We recently reported an important role for A34 in proper
targeting and incorporation of B5 into progeny virions utilizing a
recombinant virus that has A34R deleted and expresses B5R-GFP in
place of B5R (Earley et al., 2008). In addition to B5 and A34, A33 has
been shown to be required for efﬁcient cell-to-cell spread as deletion
of A33R results in a reduction in plaque size (Roper et al., 1998). In a
similar way, we constructed a recombinant virus that has A33R
deleted and expresses B5R-GFP to study IEV/EVmorphogenesis in the
absence of A33. The new recombinant, vB5R-GFP/ΔA33R, formed
plaques that ﬂuoresced green and were noticeably smaller than
plaques formed by the parental A33R deletion virus, vΔA33R, (Fig. 1).
The two analogous viruses, WR and vB5R-GFP, formed plaques that
were similar in size and much larger than those formed by either
ΔA33R virus. Plaque size is related to the amount of infectious EV
produced and the ability to form actin tails (Blasco and Moss, 1991;Fig. 1. Plaque phenotypes. Conﬂuent BS-C-1 cell monolayers were infected with the ind
ﬂuorescence images were captured using a ﬂuorescent microscope. Cell monolayers were sta
enlarged plaque in the boxed area. Schematic representation of the genome of each recomWard and Moss, 2001b). The deletion of A33R abrogates the
production of actin tails, therefore, the smaller plaques formed by
vB5R-GFP/ΔA33R suggest that the addition of GFP to the cytoplasmic
tail of B5 in the absence of A33 is affecting the production of infectious
enveloped virions. To test this idea, B5R-GFPwas replaced with B5R in
vB5R-GFP/ΔA33R to create vB5R/ΔA33R. This replacement restored
the plaque size of vB5R/ΔA33R to that of vΔA33R, indicating that the
smaller plaque phenotype of vB5R-GFP/ΔA33R is due to the addition
of GFP to the cytoplasmic tail of B5.B5-GFP is mis-targeted in the absence of A33
The smaller plaque phenotype of vB5R-GFP/ΔA33R compared to
vΔA33R suggests that in the absence of A33, the addition of GFP to the
cytoplasmic tail of B5 results in a decrease in the amount of infectious
EV produced. This could be due to a decrease in the total amount of EV
produced, their infectivity or a combination of both. To determine
where the defect was occurring, we looked at the localization of B5 in
cells infected with our recombinant viruses by immunoﬂuorescence
microscopy. Typically, cells infected with vB5R-GFP display three
characteristic hallmarks of GFP ﬂuorescence: an accumulation of GFP
ﬂuorescence at the site of wrapping in the juxtanuclear region, at the
cell vertices, and GFP-labeled virion-sized particles (VSPs) in the
cytoplasm (Fig. 2). Cells infected withWR had a similar B5 localization
pattern to that seen in cells infected with vB5R-GFP (Fig. 2). In cells
infected with either vΔA33R or vB5R/ΔA33R, B5 localized at the site
of wrapping and on VSPs (Fig. 2). In contrast, cells infected with vB5R-
GFP/ΔA33R displayed a GFP ﬂuorescence pattern different from that
seen in cells infected with vΔA33R (Fig. 2). B5-GFP was found
throughout the cytoplasm and accumulated in the juxtanuclear region
(Fig. 2). In addition, in the absence of A33, there was a distinct
reduction in GFP-labeled VSPs in the cytoplasm, suggesting that B5-
GFP was not efﬁciently incorporated into progeny enveloped virionsicated viruses and overlaid with semi-solid media. Two days PI, phase contrast and
ined with crystal violet three days PI and imaged. For vB5R-GFP/ΔA33R, insert shows an
binant virus is shown below the ﬂuorescence images.
Fig. 2. B5-GFP is mis-targeted in the absence of A33. HeLa cells were infected with the indicated viruses at a MOI of 1.0. At 24 h PI, ﬁxed and permeabilized cells were stained with an
anti-B5 MAb, followed by Texas Red-conjugated donkey anti-rat antibody (red), and visualized using a ﬂuorescent microscope. Localization of B5-GFP or B5 at the site of wrapping
(concave arrowheads), at the vertices (arrows), and on virion-sized particles (arrowheads) is indicated. The DNA in nuclei and viral factories was stained with DAPI (blue). B5-GFP is
shown in green. The overlap of green and red is shown in yellow.
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ﬂuorescencewith B5 staining in cells infectedwith either vB5R-GFP or
vB5R-GFP/ΔA33R indicated that the GFP ﬂuorescence was a true
representation of the localization of B5 fused to GFP (Fig. 2). In
addition, Western blot analysis of the lysates of cells infected with
vB5R-GFP or vB5R-GFP/ΔA33R indicated that the B5-GFP chimera
was intact in the absence of A33 (data not shown).A33 is required for proper targeting of B5-GFP
We wanted to determine if proper B5-GFP localization could be
restored in cells infected with vB5R-GFP/ΔA33R by providing the
A33R gene in trans. Therefore, we performed in vivo trans-comple-
mentation, followed by immunoﬂuorescence microscopy. A plasmid
that expresses A33R with an HA epitope tag under its own promoter
was constructed (pA33R-HA-118). Cells infected with vB5R-GFP were
transfected with the empty vector pBMW118, (Ward, 2009), while
cells infected with vB5R-GFP/ΔA33R were transfected with either
pBMW118 or pA33R-HA-118. Both plasmids contain the coding
sequence of the HcRed gene under control of the vaccinia virus
modiﬁed H5 promoter, therefore, cells that are both transfected and
infected are easily identiﬁed by the expression of HcRed. Cells infected
with vB5R-GFP/ΔA33R and transfected with pA33R-HA-118 ﬂuo-
resced red and displayed a GFP ﬂuorescence pattern identical to that
seen in cells infected with vB5R-GFP (Fig. 3). In contrast, cells infected
with vB5R-GFP/ΔA33R and transfected with pBMW118 ﬂuoresced
red and displayed the mis-targeted B5-GFP ﬂuorescence pattern(Fig. 3). The staining of A33 with anti-HA MAb indicated that A33-HA
is recognized by the antibody and suggests that the HA epitope tagged
A33R localized properly in these infections (Fig. 3). In addition, the
ability of A33-HA to restore proper targeting of B5-GFP in cells
infected with vB5R-GFP/ΔA33R suggests that the aberrant localiza-
tion of B5-GFP is due solely to the absence of A33.
Targeting of B5-GFP to the site of wrapping is partially defective in the
absence of A33
We previously reported that the interaction of A34 and B5-GFP is
required for the efﬁcient trafﬁcking of B5-GFP from the ER to the site of
wrapping (Earley et al., 2008). Similarly, we wanted to examine, at the
subcellular level, the localization of B5-GFP in the absence of A33. We,
therefore, stained cells infected with vB5R-GFP, WR, vΔA33R, or vB5R-
GFP/ΔA33R with anti-Calnexin and anti-golgin-97 antibodies to visual-
ize the localization of B5-GFP or B5 relative to the ER and TGN resident
proteins, respectively. As shown in Fig. 4, both B5-GFP and B5 localized
with golgin-97. However, there appeared to bemore B5-GFP localization
with Calnexin throughout the cytoplasm in the absence of A33 (Fig. 4).
B5-labeled VSPs are not present on the surface of cells infected with
vB5R-GFP/ΔA33R
On the surface of infected cells, B5 is typically found on the plasma
membrane and on virion-sized particles, i.e., CEV. To look for B5 in the
absence of A33, we stained unpermeabilized cells infected with vB5R-
Fig. 3. A33 is required for proper targeting of B5-GFP. HeLa cells were infected with the indicated viruses at a MOI of 1.0 and transfected with the indicated plasmids. 24 h PI, cells
were ﬁxed, permeabilized, and A33-HA was visualized by staining with an anti-HA MAb, followed by Cy-5-labeled donkey anti-rat antibody (red). Inserts show HcRed ﬂuorescence
(orange), indicating that cells were transfected and infected. Localization of B5-GFP or A33-HA at the site of wrapping (concave arrowheads), at the vertices (arrows), and on virion-
sized particles (arrowheads) is indicated. The DNA in nuclei and viral factories was stained with DAPI (blue). B5-GFP is shown in green. The overlap of green and red is shown in
yellow.
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MAb. B5-labeled VSPs were seen on the surface of cells infected with
vB5R-GFP, WR, vΔA33R, or vB5R/ΔA33R (Fig. 5). In contrast, there
were little to no VSPs stained on the surface of cells infected with
vB5R-GFP/ΔA33R although B5-GFP appeared to be efﬁciently depos-
ited onto the plasma membrane (Fig. 5), suggesting that A33 is
required for the incorporation of B5-GFP into progeny enveloped
virions while A33 is not required for the incorporation of B5 into
progeny enveloped virions.
B5-GFP is not efﬁciently incorporated into progeny virions in the absence
of A33
Our previous result suggests that little to no B5-GFP is incorpo-
rated into progeny enveloped virions in the absence of A33 (Fig. 6). To
test this, radiolabeled EEV released by RK13 cells infected with vB5R-
GFP, vB5R-GFP/ΔA33R, WR, or vΔA33R were puriﬁed. The resulting
viral pellet was lysed and equal amounts of radiation were subjected
to immunoprecipitation with either an anti-B5 or anti-F13 MAb. Both
B5-GFP or B5 and F13 were precipitated from EEV released by cells
infected with vB5R-GFP, WR, or vΔA33R. In contrast, B5-GFP was not
precipitated from EEV released by cells infected with vB5R-GFP/
ΔA33Rwhile F13was immunoprecipitated (Fig. 6A), indicating that in
the absence of A33, B5-GFP is not efﬁciently incorporated into EEV.
The examination of equilibrated EEV lysates on SDS-PAGE showedthat approximately equal amounts of protein were used in the assay
(Fig. 6A).
To verify these results, we performed immunoelectronmicroscopy
on puriﬁed EEV and IMV, which allows us to directly visualize the
incorporation of B5 into enveloped virions. Puriﬁed EEV released from
cells infected with vB5R-GFP, WR, vΔA33R, or vB5R-GFP/ΔA33R and
puriﬁed IMV from cells infected with either vΔA33R or vB5R-GFP/
ΔA33R were immunolabeled with an anti-B5 MAb and rabbit anti-L1
antibody, which are speciﬁc for proteins found in the EEV membrane
and IMV membrane, respectively, followed by 18 nm and 6 nm
colloidal gold-conjugated secondary antibodies. Anti-B5 MAb readily
labeled EEV released from cells infected with vB5R-GFP, WR, or
vΔA33R but not vB5R-GFP/ΔA33R (Fig. 6B). With the exception of
EEV from cells infected with vB5R-GFP/ΔA33R, L1 was readily
detected on all of the virions, including the IMV from cells infected
with vB5R-GFP/ΔA33R. The L1 staining of EV is likely due to ruptures
in the EV membrane that occurred during processing of the samples,
which exposed the IMV antigens. EV that lack B5 were reported to
have a more stable outer envelope (Roberts et al., 2009). This stability
likely accounts for the lack of L1 staining of the EV particles released
from cells infected with vB5R-GFP/ΔA33R as they do not contain B5.
Taken together, our data indicate that A33 is required for the
incorporation of B5-GFP into progeny enveloped virions while B5 is
efﬁciently incorporated into progeny enveloped virions in the absence
of A33.
Fig. 4.More B5-GFP localizes to the ER. HeLa cells were infected with the indicated viruses at a MOI of 1.0. 12 h PI, cells were ﬁxed, permeabilized, and stained with an anti-golgin-97
MAb and rabbit anti-Calnexin antibody, followed by Cy5-conjugated goat anti-mouse (red) and Texas Red-conjugated donkey anti-rabbit (red) antibodies. Cells infected with either
WR or vΔA33R were subsequently stained with an anti-B5 MAb, followed by FITC-conjugated donkey anti-rat antibody (green). Immunostained cells were imaged using a
ﬂuorescent microscope to visualize the localization of B5-GFP or B5 relative to the TGN and ER resident proteins, golgin-97 and Calnexin, respectively. The DNA in nuclei and viral
factories was stained with DAPI (blue). The overlap of green (B5-GFP or B5) and red (golgin-97 or Calnexin) is shown in yellow.
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B5 has been reported to play a role in the dissolution of the
outermost membrane of EEV to allow IMV to enter cells (Roberts et al.,
2009). Therefore, the smaller plaque phenotype of vB5R-GFP/ΔA33R
suggests two possibilities: less enveloped virions are produced by
vB5R-GFP/ΔA33R compared to vΔA33R or enveloped virions pro-
duced by vB5R-GFP/ΔA33R are less infectious as they lack B5. To test
these possibilities, we quantiﬁed the amounts of infectious and total
EEV and CEV produced by vB5R-GFP, vΔA33R, and vB5R-GFP/ΔA33R
after 24 h of infection using plaque assays and real time PCR,
respectively. As shown in Figs. 7A and 7B, vΔA33R produced more
total EEV, as measured by the copies of genomes, than vB5R-GFP/
ΔA33R and more infectious EEV, as measured by plaque forming unit(PFU). In accordance with previously published data that compared
WR to vΔA33R, vΔA33R produced 3 fold more infectious EEV than
vB5R-GFP (Fig. 7A) (Roper et al., 1998). However, vΔA33R produced
28 fold more EEV genomes compared to vB5R-GFP, indicating that
EEV produced by vΔA33R are not fully infectious (Fig. 7). Next, the
number of genome copies was compared to PFUs to determine their
infectivity. Whereas 1 out of every 1.6 genome copies resulted in a
plaque for vB5R-GFP, this number was greatly elevated to 1 out of
every 12.9 genome copies in the absence of A33 indicating that the
absence of A33 on EEV is detrimental to their infectivity. Surprisingly,
the absence of B5 from vΔA33R caused a reduction of this number to 1
out of every 6.1 genome copies resulting in a plaque (Fig. 7C).We next
performed a similar analysis on virions released from the cell surface
by trypsin treatment. Both vB5R-GFP/ΔA33R and vΔA33R produced
Fig. 5. A33 is required for efﬁcient incorporation of B5-GFP into enveloped virions on the surface of cells. HeLa cells were infected with the indicated viruses at a MOI of 1.0. 24 h PI,
cells were ﬁxed and stained with an anti-B5 MAb, followed by Texas Red-conjugated donkey anti-rat antibody (red). Immunostained cells were imaged using a ﬂuorescent
microscope. The DNA in nuclei and viral factories was stained with Hoechst (blue). B5-GFP is shown in green. Merged images of green and red are shown in yellow.
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similar between the three viruses (Fig. 7). Similar to EEV, CEV
produced by vΔA33R and vB5R-GFP/ΔA33R was less infectious
compared to vB5R-GFP. By adding the numbers obtained for EEV
and CEV, we quantiﬁed the amount of EV produced by all three
viruses. Whereas the total number of genomes released by vΔA33R
and vB5R-GFP/ΔA33R were very similar, vB5R-GFP/ΔA33R produced
less infectious EV than vΔA33R, indicating that EV productionmay not
be the reason for the difference in plaque size (Fig. 7).
EEV produced by A33R-deﬁcient viruses do not efﬁciently bind BS-C-1
cells
It has been suggested that B5 has a role in cell binding (Smith et al.,
2002). Therefore, the reduction in the infectivity of EV produced by
vB5R-GFP/ΔA33R could be due to a reduction in cell binding. To test
this, we equilibrated fresh EEV from cells infected with vB5R-GFP,
vB5R-GFP/ΔA33R, or vΔA33R using real-time PCR and quantiﬁed
their ability to bind BS-C-1 cells using immunoﬂuorescence micros-
copy. EEV produced by vB5R-GFP, vB5R-GFP/ΔA33R or vΔA33R were
labeled with anti-F13 MAb on the surface of BS-C-1 cells indicatingthat they are capable of binding cells (data not shown). To quantify
the amount of binding, 200 nuclei were imaged and the number of
labeled VSPs was counted. Fewer EEV produced by either vB5R-GFP/
ΔA33R or vΔA33R bound to the cells compared to those produced by
vB5R-GFP, indicating EEV produced by A33R-deﬁcient viruses do not
efﬁciently bind BS-C-1 cells (Fig. 8). In addition, our data indicate that
the absence of B5 on EEV did not affect their ability to bind BS-C-1
cells as similar number of bound EEVs was detected for both vB5R-
GFP/ΔA33R and vΔA33R.
Discussion
Initially, we wanted to use B5-GFP to track IEV production in the
absence of A33 but found that a virus that has A33R deleted and
expresses B5-GFP in place of B5 formed plaques that were smaller
than the parental virus that only had A33R deleted. This was
surprising because a recombinant virus that has B5R replaced with
B5R-GFP appears to be similar to its parental virus, WR (Fig. 1) (Ward
andMoss, 2001a).We have determined that the addition of GFP to the
cytoplasmic tail prevents the incorporation of B5 into EV in the
absence of A33. This ﬁnding points to the cytoplasmic tail of B5 as an
Fig. 6. A33 is required for efﬁcient incorporation of B5-GFP into EEV. RK13 cells were infected with the indicated viruses at a MOI of 10.0 and incubated with media containing [35S]-
Met/Cys. 24 h PI, supernatants were collected, clariﬁed, and loaded onto a 36% sucrose cushion to purify EEV. (A) Immunoprecipitation. Puriﬁed EEVwere resuspended in RIPA buffer
and equal amounts of radiation from each were subjected to immunoprecipitation with either an anti-B5 or anti-F13 MAb. Immune complexes were resolved by SDS-PAGE and
radiolabeled proteins were detected by autoradiography. Equilibrated crude EEV lysates were analyzed to show that comparable amounts were used for each immunoprecipitation.
The molecular weights in kDa and positions of marker proteins are shown. (B) Immunoelectron microscopy. Puriﬁed EEV and IMV were immunolabeled with an anti-B5 MAb and
rabbit anti-L1 antibody, followed by 18 nm colloidal gold-conjugated goat anti-rat and 6 nm colloidal gold-conjugated goat anti-rabbit antibodies. Immunogold-labeled virions were
negative-stained and visualized using a TEM. A representative virion from each is shown. Scale bars represent 50 nm.
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this may seem at odds with previous reports that the cytoplasmic tail
of B5 was dispensable for EV formation and incorporation (Lorenzo
et al., 1998; Mathew et al., 1998), both of these studies were carried
out in the presence of A33. One explanation is that GFP is preventing
the interaction of the cytoplasmic tail of B5 with some other protein,
either viral or cellular, that targets B5 to the EV membrane in the
absence of A33. A likely viral protein candidate would be F13, which is
found exclusively on the cytoplasmic side of the membrane and was
recently shown to coimmune precipitate B5 (Chen et al., 2009). In
addition, the cytoplasmic tail of B5 was shown to have two cellular
targeting motifs, a membrane-proximal tyrosine-based endocytosis
signal and a C-terminal dileucine signal (Ward andMoss, 2000). These
signals interact with various adapter proteins (AP) for incorporationinto clatherin-coated vesicles and intracellular transport between the
compartments of the endomembrane system including bi-directional
transport between the trans-Golgi network and the plasma mem-
brane (Robinson, 2004). It is not difﬁcult to imagine that this
trafﬁcking could target B5-GFP to the proper location for EV
incorporation. Although it should be pointed out that these signals
were shown to be functional for plasma membrane retrieval of B5-
GFP in the absence of infection (Ward and Moss, 2000).
Our results suggest that inclusion into the IEV/EV membrane is an
active process and therefore, only select viral membrane proteins get
incorporated. Alternatively, incorporation into EV may be passive and
that the addition of GFP to B5 actively inhibits its incorporation. This
seems unlikely when considering that unmodiﬁed A36 requires an
interaction with A33 to be targeted to the IEVmembrane (Ward et al.,
Fig. 7. The majority of EEV and CEV produced by A33-deﬁcient viruses are not infectious. BS-C-1 cells were infected with the viruses indicated on the X-axes at a MOI of 10.0. 24 h PI,
EEV containing culture supernatants were collected and a trypsin release assay was performed on cell monolayers to quantify CEV. (A) The amounts of infectious EEV or CEV
produced (PFU/ml) were determined by a plaque assay on BS-C-1 monolayers. (B) The total amounts of EEV or CEV produced were determined by absolute quantiﬁcation of genome
copies (GC/ml) using real time PCR. For EV, the amount of EEV and CEV quantiﬁed by either PFU (A) or GC (B) were added together. Error bars are plotted for each virus. The fold
difference relative to vB5R-GFP is shown. (C) Both PFU and GC of EEV, CEV or EV were plotted and the fold difference between PFU and GC is shown.
90 W.M. Chan, B.M. Ward / Virology 402 (2010) 83–932003;Wolffe et al., 2001). Furthermore, similar to A36, B5 and B5-GFP
have been shown to interact with A33 (Perdiguero and Blasco, 2006;
Chan and Ward, unpublished results). It is tempting to speculate that
B5-GFP requires an interaction with A33 for inclusion into IEV/EV.
However, it was reported, using ﬂuorescence microscopy, that DNA
staining particles in infected cells colocalizedwith B5 in the absence of
A33 but not with A33 in the absence of B5 (Perdiguero and Blasco,
2006). It was concluded that A33 requires B5 for incorporation into
IEV/EV membranes but B5 does not require A33. This result is incontrast to a similar study in which particles in the cytoplasm of
infected cells were stained, albeit infrequently, with both A27 and A33
in the absence of B5 (Rottger et al., 1999). Furthermore, Rottger et al.
reported that actin tails were formed, a process that requires A33 for
the incorporation of A36, in the absence of B5. Using both
immunoprecipitation and immunoelectron microscopy, we con-
ﬁrmed that B5 was incorporated into EV in the absence of A33 but
B5-GFP was not. Similarly, we were able to detect F13 on puriﬁed EV
made in the absence of A33, albeit at reduced levels which supports
Fig. 8. EEV produced by A33R-deﬁcient viruses bind less efﬁciently to BS-C-1 cells. EEV
released from cells infected with the indicated viruses were collected and the number
of viral genomes released by each virus was determined by real time PCR. The same
number of genome copies for each virus was bound to BS-C-1 cells at 4 °C for 1 h.
Unbound virions were removed by washing. Cells were ﬁxed, permeabilized, and
stained with an anti-F13 MAb, followed by Texas Red-conjugated donkey anti-mouse
antibody. DNA in the nuclei was stained with DAPI and 200 nuclei were imaged. The
number of F13-labeled VSPs was counted. The average of two independent experiments
is shown and error bars are plotted for each virus.
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EV. Indeed, F13was previously found in EV by immuno-EM of infected
cells and by Western blot of puriﬁed virions (Roberts et al., 2009;
Roper et al., 1998).
For orthopoxviruses, plaque formation is a multistep-process that
utilizes no less than six IEV/EV speciﬁc proteins.With the exception of
A56R, deletion of any individual vaccinia virus IEV/EV speciﬁc protein
leads to a reduction in plaque size on cell monolayers, but not a
complete abrogation. A priori, one could predict that plaque size is
directly related to the amount of infectious EV produced. A small
plaque phenotype could be due to a decrease in EV production, and/or
a decrease in their infectivity. We have quantiﬁed the amount of EV
produced by vB5R-GFP, vΔA33R, and vB5R-GFP/ΔA33R and their
infectivity. The deletion of A33 seems to have only a small effect on
the amount of EV produced as measured by genome copy. In contrast,
the absence of A33 decreases the infectivity of EEV almost 10 fold. This
could account for the reduction in plaque size seen between WR/
vB5R-GFP and vΔA33R except that the total amount of infectious EEV
released by vΔA33R is 3.5× greater (Fig. 7 and (Roper et al., 1998)). A
more likely explanation is the greater reduction of infectious CEV and
loss of actin tail formation by vΔA33R. Indeed, the abrogation of actin
tail formation has been shown to result in a 3-fold reduction in plaque
size (Ward and Moss, 2001a).
After our initial observation that vB5R-GFP/ΔA33R forms plaques
that are smaller than the parental virus vΔA33R (Fig. 1), we sought to
determine the underlying mechanism. Although a fraction of B5-GFP
appears to bemis-targeted in the absence of A33 (Fig. 4), this does not
appear to have a large effect on EV production. Subsequently, we
determined that in the absence of A33, B5-GFP was not incorporated
into EV while B5 was. Our data suggest that the difference in plaque
size between these two viruses is due to the reduced amounts of
infectious EV produced by vB5R-GFP/ΔA33R. Our data also suggest
that the presence of B5 does not enhance EEV binding. Therefore, B5
must have a role other than cell binding during infection. One
possibility is EV membrane dissolution, which is required to liberate
IMV from the EV membrane in subsequent infection (Law et al., 2006;
Roberts et al., 2009).
Surprisingly, vB5R-GFP, vΔA33R and vB5R-GFP/ΔA33R released
similar amounts of EV. B5 is thought to have a function in IEVformation and egress and therefore B5 either does not require EV
incorporation to perform this function, or other viral proteins can
compensate for the lost function. In a similar fashion, the small
reduction in EV production seen in the absence of A33 could be due to
either a small function in EV production/egress, or compensation by
other proteins for the lost function. The results presented here
support the latter idea. Given the importance of EV for the spread of
orthopoxviruses, it seems highly likely that other proteins are, to
some extent, able to compensate for missing functions. This idea is
supported by the fact that IEV/EV production cannot be completely
abrogated by deleting any individual IEV/EV speciﬁc gene.
Our results show that the absence of A33 causes a shift of CEV to
EEV. Previous reports have attributed CEV retention in part to the
putative C-type lectin domain of A34 (Blasco et al., 1993). It is possible
that the absence of A33 has an indirect effect on A34 and the retention
of CEV on the cell surface. Alternatively, a recent paper describing the
crystal structure of A33 produced in bacteria indicates that it also has
a lectin-like domain that could potentially bind ligands (Su et al.,
2010), raising the possibility that A33 is directly involved in the
retention of CEV. This would indicate that both A33 and A34 are
independently involved in CEV retention. In the absence of A33, there
was a substantial number of CEV released by trypsin suggesting that
other EV proteins are capable of retaining CEV in the absence of A33,
and that A33 and A34 may have a cumulative effect on CEV retention.
Materials and methods
Cells and viruses
Monolayers of HeLa, BS-C-1, and RK13 cells were maintained as
previously described (Ward, 2005). Construction of vB5R-GFP and
vΔA33R has been described previously (Roper et al., 1998; Ward and
Moss, 2001b). To construct vB5R-GFP/ΔA33R, cells infected with
vΔA33R were transfected with pB5R-GFP (Ward and Moss, 2001b). A
recombinant virus that has A33R deleted and expresses B5R-GFP was
screened and ampliﬁed as previously described (Earley et al., 2008).
To construct vB5R/ΔA33R, cells infected with vB5R-GFP/ΔA33R were
transfected with a plasmid containing the coding sequence of B5R and
500 bp upstream and downstream regions. Plaques that did not
ﬂuoresce green were selected and ampliﬁed. The coding sequence of
B5-GFP or B5 in each virus was veriﬁed by sequencing.
Plaque assay
The procedure for imaging plaque assays has been described
previously (Ward, 2005). Brieﬂy, conﬂuent BS-C-1 monolayers were
infected with vB5R-GFP, WR, vΔA33R, vB5R-GFP/ΔA33R, or vB5R/
ΔA33R and overlaid with semi-solid media. Two days after infection,
phase contrast and ﬂuorescence images of plaques were captured
using a ﬂuorescent microscope. Cell monolayers were stained with
crystal violet three days after infection and imaged.
Plasmid constructs
Construction of pBMW118 and pB5R-GFP has been described
previously (Ward, 2009; Ward and Moss, 2001b). The 500 bp
upstream region and the coding sequence of A33R followed by the
hemagglutinin (HA) epitope sequence was inserted into pBMW118 to
make pA33R-HA-118. The construct was veriﬁed by sequencing.
Immunoﬂuorescence microscopy
For in vivo trans-complementation, HeLa cells grown on glass
coverslips and infected with either vB5R-GFP or vB5R-GFP/ΔA33R
at a multiplicity of infection (MOI) of 1.0 were transfected with
either pBMW118 or pA33R-HA-118 at 2 h post infection (PI) using
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The followingday, cellswereﬁxed, permeabilized, and incubatedwith an
anti-HA MAb (Roche), followed by Cy5-conjugated donkey anti-rat
antibody (Jackson ImmunoResearch Laboratories). Stained cells were
mounted in Mowiol containing 1 μg per ml of 4′,6-diamidino-2-
penylindole dihydrochloride (DAPI) (EM sciences). For subcellular
localization, HeLa cells were infected at a MOI of 1.0. The following day,
cells were ﬁxedwith 4% paraformaldehyde and permeabilizedwith 0.1%
Triton X-100, both in phosphate buffered saline (PBS). The following
antibodies were used for staining: anti-B5 MAb (19C2), (Hooper et al.,
2000; Schmelz et al., 1994), anti-Calnexin antibody (Stressgen), anti-
golgin-97 MAb (Invitrogen, Molecular Probes). For surface staining,
infected cells were ﬁxed and incubated with an anti-B5 MAb on ice,
followed by incubation with Texas Red-conjugated donkey anti-rat
antibody (Jackson ImmunoResearch Laboratories). Stained cells were
incubatedwith 0.5 mgperml of Hoechst. Cellswere imaged using a Leica
DMIRB inverted ﬂuorescent microscope connected to a cooled charged-
coupled device (Cooke) controlled by Image-Pro Plus software (Meida-
Cybernetics). Images were colored, minimally processed, and overlaid
using Adobe Photoshop (Adobe).
EEV isolation and immunoprecipitation
RK13 cells were infected with vB5R-GFP,WR, vΔA33R, or vB5R-GFP/
ΔA33R at a MOI of 10.0. 2 h later, the inoculum was removed and
replaced with fresh media. 4 h PI, media was replaced with media
containing 25 μCi per ml of [35S]-Met/Cys (Perkin Elmer). 24 h PI,
supernatants were collected and spun at 225 ×g to remove cell debris.
To purify EEV, clariﬁed supernatants were centrifuged through a 36%
sucrose cushion at 140,000 ×g for 20 min. Puriﬁed EEV were lysed in
radioimmunoprecipitation assay (RIPA) buffer (0.5× phosphate buff-
ered saline, 0.1% sodiumdodecyl sulfate, 1% TritonX-100, 1%NP-40, and
0.5% sodium deoxycholate) containing protease inhibitors on ice for
20 min. B5 or F13 was immunoprecipitated from equilibrated lysates
with either an anti-B5 or anti-F13MAb (kindly provided by Jay Hooper)
as previously described (Earley et al., 2008). Bound immune complexes
werewashed three times in RIPA buffer, resolved on 4–12% Bis–Tris gels
(Invitrogen), and detected by autoradiography. Crude equilibrated EEV
lysates were analyzed to show that equal amounts of lysates were used
in each immunoprecipitation.
Immunoelectron microscopy
RK13 cells were infected with vB5R-GFP,WR, vΔA33R, or vB5R-GFP/
ΔA33R at a MOI of 5.0. 2 h PI, inoculum was removed and cells were
washed three timeswith freshmedia to remove unbound virus. 48 h PI,
EEV were puriﬁed through a 36% sucrose cushion as described above.
The procedure for puriﬁcation of IMV has been described previously
(Earl and Moss, 1991). To visualize virions by immunoelectron
microscopy, puriﬁed IMV or EEV were adsorbed to Formvar-coated
nickel grids (EM Sciences). Grids werewashed in 0.2% glycine in PBS for
5 min, blockedwith1%BSA inPBS for45 min.Gridswere incubatedwith
an anti-B5 MAb and rabbit anti-L1 antiserum (kindly provided by Gary
H. Cohen and Roselyn J. Eisenberg) followed by 18 nm colloidal gold-
conjugated goat anti-rat and 6 nm colloidal gold-conjugated goat anti-
rabbit antibodies (Jackson ImmunoResearch Laboratories). Immuno-
gold-labeled EEV and IMVwere negative-stained and visualized using a
Hitachi 7650 TEM with a Gatan 11 Megapixel digital camera.
Quantiﬁcation of EEV and CEV
Todetermine the amount of EEV and CEV produced by A33-deﬁcient
viruses, BS-C-1 cells were infected with vB5R-GFP, vΔA33R, or vB5R-
GFP/ΔA33R at a MOI of 10.0 in duplicate. 2 h PI, the inoculum was
removed and cell monolayers were washed with phosphate buffered
saline to remove unbound virus. 1.0 ml of EMEM containing no serum(EMEM−) was added to each well. 24 h PI, supernatants were collected
and centrifuged to remove detached cells. Clariﬁed supernatants were
transferred to fresh tubes and the amount of EEV in the culture
supernatant was determined by a plaque assay and real time PCR as
described below. After EEV containing supernatants were collected, a
trypsin release assay was performed on cell monolayers as previously
described (Blasco and Moss, 1992). Brieﬂy, cell monolayers were
washedwith EMEM− twice. 1.0 ml of EMEM− containing1 µg of trypsin
per mlwas added to eachwell and cells were incubated at 37 °C for 1 h.
After incubation, supernatants were collected and centrifuged to
remove detached cells. Clariﬁed supernatants were transferred to
fresh tubes and the amount of CEV in the media was determined by a
plaque assay and real time PCR as described below. The amounts of
infectious EEV and CEV were determined by a plaque assay on BS-C-1
cells. For absolute quantiﬁcation of EEV and CEV, viral genomes were
isolated using Wizard plus minipreps DNA puriﬁcation system (Pro-
mega) following manufacturer's instructions. TaqMan probes and
primers speciﬁc for E9L were generated. Real time PCR was performed
in quadruplicate for each sample using TaqMan Universal PCR Master
Mix (Applied Biosystems) following manufacturer's instructions.
Binding assay
BS-C-1 cells were infected with vB5R-GFP, WR, vΔA33R, or vB5R-
GFP/ΔA33R at a MOI of 10.0. 24 h PI, supernatants were collected and
clariﬁed as described above. The number of viral genomes released by
each virus was determined by real time PCR as described above. An
equal number of genomes for each virus was bound to BS-C-1 cells
grown on poly-D-lysine treated glass coverslips on ice for 1 h.
Unbound virions were removed by washing. Cells were ﬁxed with
4% paraformaldehyde overnight, and permeabilized with 0.1% Triton
X-100. Cells were stained with an anti-F13 MAb, followed by Texas
Red-conjugated donkey anti-mouse antibody (Jackson ImmunoRe-
search Laboratories). Stained cells were mounted in Mowiol contain-
ing DAPI as described above. For quantiﬁcation, 200 nuclei were
imaged and the number of F13-labeled VSPs counted.
Acknowledgments
We thank BernardMoss for the recombinant viruses and plasmids.
We thank Jay Hooper for the anti-F13 MAb, Gary H. Cohen and
Roselyn J. Eisenberg for the anti-L1 antisera. We also thank the
Electron Microscope Research Core at the University of Rochester
Medical Center and Karen Bentley for her help in developing the
protocol for the EM study. Parts of this work were funded by the
National Institute of Allergy and Infectious Diseases grant AI067391
and contract N01-AI-50020. WMC is supported by the National
Institute of Allergy and Infectious Diseases Molecular Pathogenesis of
Bacteria and Viruses Training Grant T32 AI007362.
References
Appleyard, G., Hapel, A.J., Boulter, E.A., 1971. An antigenic difference between
intracellular and extracellular rabbitpox virus. J. Gen. Virol. 13, 9–17.
Blasco, R., Moss, B., 1991. Extracellular vaccinia virus formation and cell-to-cell virus
transmission are prevented by deletion of the gene encoding the 37,000- Dalton
outer envelope protein. J. Virol. 65 (11), 5910–5920.
Blasco, R., Moss, B., 1992. Role of cell-associated enveloped vaccinia virus in cell-to-cell
spread. J. Virol. 66 (7), 4170–4179.
Blasco, R., Sisler, J.R., Moss, B., 1993. Dissociation of progeny vaccinia virus from the cell
membrane is regulated by a viral envelope glycoprotein: effect of a point mutation
in the lectin homology domain of the A34R gene. J. Virol. 67 (6), 3319–3325.
Chen, Y., Honeychurch, K.M., Yang, G., Byrd, C.M., Harver, C., Hruby, D.E., Jordan, R.,
2009. Vaccinia virus p37 interacts with host proteins associated with LE-derived
transport vesicle biogenesis. Virol. J. 6, 44.
Duncan, S.A., Smith, G.L., 1992. Identiﬁcation and characterization of an extracellular
envelope glycoprotein affecting vaccinia virus egress. J. Virol. 66, 1610–1621.
Earl, P.L., Moss, B., 1991. In: Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D.,
Seidman, J.G., Smith, J.A., Struhl, K. (Eds.), Generation of Recombinant Vaccinia
93W.M. Chan, B.M. Ward / Virology 402 (2010) 83–93Viruses. Current Protocols inMolecular Biology, vol. 2. Greene Publishing Associates &
Wiley Interscience, New York, pp. 16.17.1–16.17.16.
Earley, A.K., Chan, W.M., Ward, B.M., 2008. The vaccinia virus B5 protein requires A34
for efﬁcient intracellular trafﬁcking from the endoplasmic reticulum to the site of
wrapping and incorporation into progeny virions. J. Virol. 82 (5), 2161–2169.
Engelstad, M., Howard, S.T., Smith, G.L., 1992. A constitutively expressed vaccinia gene
encodes a 42-kDa glycoprotein related to complement control factors that forms
part of the extracellular virus envelope. Virology 188, 801–810.
Geada, M.M., Galindo, I., Lorenzo, M.M., Perdiguero, B., Blasco, R., 2001. Movements of
vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope
protein. J. Gen. Virol. 82 (Pt 11), 2747–2760.
Hiller, G., Weber, K., 1985. Golgi-derived membranes that contain an acylated viral
polypeptide are used for vaccinia virus envelopment. J. Virol. 55 (3), 651–659.
Hirt, P., Hiller, G., Wittek, R., 1986. Localization and ﬁne structure of a vaccinia virus
gene encoding an envelope antigen. J. Virol. 58, 757–764.
Hollinshead, M., Rodger, G., Van Eijl, H., Law, M., Hollinshead, R., Vaux, D.J., Smith, G.L.,
2001. Vaccinia virus utilizes microtubules for movement to the cell surface. J. Cell
Biol. 154 (2), 389–402.
Hooper, J.W., Custer, D.M., Schmaljohn, C.S., Schmaljohn, A.L., 2000. DNA vaccination
with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus
challenge. Virology 266 (2), 329–339.
Isaacs, S.N., Wolffe, E.J., Payne, L.G., Moss, B., 1992. Characterization of a vaccinia virus-
encoded 42-kilodalton class I membrane glycoprotein component of the extracel-
lular virus envelope. J. Virol. 66 (12), 7217–7224.
Law, M., Carter, G.C., Roberts, K.L., Hollinshead, M., Smith, G.L., 2006. Ligand-induced
and nonfusogenic dissolution of a viral membrane. Proc. Natl. Acad. Sci. U. S. A. 103
(15), 5989–5994.
Lorenzo, M.D., Herrera, E., Blasco, R., Isaacs, S.N., 1998. Functional analysis of vaccinia
virus B5R protein: role of the cytoplasmic tail. Virology 252 (2), 450–457.
Mathew,E., Sanderson,C.M.,Hollinshead,M., Smith,G.L., 1998. Theextracellulardomainof
vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus
release, and intracellular actin tail formation. J. Virol. 72, 2429–2438.
Moss, B., 2001. In: Fields, B.N., Knipe, D.M., Howley, P.M. (Eds.), Poxviridae: the Viruses
and Their Replication, Fourth ed. Fields Virology, vol. 2. Lippincott-Raven Publish-
ers, Philadelphia, pp. 2849–2883. 2 vols.
Moss, B., 2006. Poxvirus entry and membrane fusion. Virology 344 (1), 48–54.
Payne, L.G., 1980. Signiﬁcance of extracellular enveloped virus in the in vitro and in vivo
dissemination of vaccinia. J. Gen. Virol. 50 (1), 89–100.
Perdiguero, B., Blasco, R., 2006. Interaction between vaccinia virus extracellular virus
envelope A33 and B5 glycoproteins. J. Virol. 80 (17), 8763–8777.
Reeves, P.M., Bommarius, B., Lebeis, S., McNulty, S., Christensen, J., Swimm, A.,
Chahroudi, A., Chavan, R., Feinberg, M.B., Veach, D., Bornmann, W., Sherman, M.,
Kalman, D., 2005. Disabling poxvirus pathogenesis by inhibition of Abl-family
tyrosine kinases. Nat. Med. 11 (7), 731–739.
Rietdorf, J., Ploubidou, A., Reckmann, I., Holmstrom, A., Frischknecht, F., Zettl, M.,
Zimmermann, T., Way, M., 2001. Kinesin-dependent movement on microtu-
bules precedes actin-based motility of vaccinia virus. Nat. Cell Biol. 3 (11),
992–1000.Roberts, K.L., Breiman, A., Carter, G.C., Ewles, H.A., Hollinshead, M., Law, M., Smith, G.L.,
2009. Acidic residues in the membrane-proximal stalk region of vaccinia virus
protein B5 are required for glycosaminoglycan-mediated disruption of the
extracellular enveloped virus outer membrane. J. Gen. Virol. 90 (Pt 7), 1582–1591.
Robinson, M.S., 2004. Adaptable adaptors for coated vesicles. Trends Cell Biol. 14 (4),
167–174.
Roper, R.L., Payne, L.G., Moss, B., 1996. Extracellular vaccinia virus envelope
glycoprotein encoded by the A33R gene. J. Virol. 70 (6), 3753–3762.
Roper, R.L., Wolffe, E.J., Weisberg, A., Moss, B., 1998. The envelope protein encoded by
the A33R gene is required for formation of actin-containing microvilli and efﬁcient
cell-to-cell spread of vaccinia virus. J. Virol. 72 (5), 4192–4204.
Rottger, S., Frischknecht, F., Reckmann, I., Smith, G.L., Way, M., 1999. Interactions
between vaccinia virus IEV membrane proteins and their roles in IEV assembly and
actin tail formation. J. Virol. 73 (4), 2863–2875.
Schmelz, M., Sodeik, B., Ericsson, M., Wolffe, E.J., Shida, H., Hiller, G., Grifﬁths, G., 1994.
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans
Golgi network. J. Virol. 68 (1), 130–147.
Smith, G.L., Vanderplasschen, A., Law, M., 2002. The formation and function of
extracellular enveloped vaccinia virus. J. Gen. Virol. 83 (Pt 12), 2915–2931.
Su, H.P., Singh, K., Gittis, A.G., Garboczi, D.N., 2010. The structure of the poxvirus A33
protein reveals a dimer of unique C-type lectin-like domains. J. Virol. 84 (5),
2502–2510.
Tooze, J., Hollinshead, M., Reis, B., Radsak, K., Kern, H., 1993. Progeny vaccinia and
human cytomegalovirus particles utilize early endosomal cisternae for their
envelopes. Eur. J. Cell Biol. 60 (1), 163–178.
van Eijl, H., Hollinshead, M., Smith, G.L., 2000. The vaccinia virus A36R protein is a type
Ib membrane protein present on intracellular but not extracellular enveloped virus
particles. Virology 271 (1), 26–36.
van Eijl, H., Hollinshead, M., Rodger, G., Zhang, W.H., Smith, G.L., 2002. The vaccinia
virus F12L protein is associated with intracellular enveloped virus particles and is
required for their egress to the cell surface. J. Gen. Virol. 83 (Pt 1), 195–207.
Ward, B.M., 2005. Visualization and characterization of the intracellular movement of
vaccinia virus intracellular mature virions. J. Virol. 79, 4755–4763.
Ward, B.M., 2009. Using ﬂuorescent proteins to study poxvirus morphogenesis.
Methods Mol. Biol. 515, 1–11.
Ward, B.M.,Moss, B., 2000. Golgi network targeting and plasmamembrane internalization
signals in vaccinia virus B5R envelope protein. J. Virol. 74 (8), 3771–3780.
Ward, B.M., Moss, B., 2001a. Vaccinia virus intracellular movement is associated with
microtubules and independent of actin tails. J. Virol. 75 (23), 11651–11663.
Ward, B.M., Moss, B., 2001b. Visualization of intracellular movement of vaccinia virus
virions containing a green ﬂuorescent protein-B5R membrane protein chimera.
J. Virol. 75 (10), 4802–4813.
Ward, B.M., Weisberg, A.S., Moss, B., 2003. Mapping and functional analysis of
interaction sites within the cytoplasmic domains of the vaccinia virus A33R and
A36R envelope proteins. J. Virol. 77 (7), 4113–4126.
Wolffe, E.J., Weisberg, A.S., Moss, B., 2001. The vaccinia virus A33R protein provides a
chaperone function for viral membrane localization and tyrosine phosphorylation
of the A36R protein. J. Virol. 75 (1), 303–310.
